Local therapy in advanced lung cancer at #ESMO26:

Narjust Florez, MD, FASCO· @NarjustFlorezMD · X·2026-10-23 23:06· 2 天前评分45

正文 · 原文

💊 Med onc: complements systemic therapy, select responders at 6 to 12 months
 ☢️ Rad onc: SINDAS positive in EGFR+, NRG-LU002 negative with IO
 ✂️ Surgery: safe and feasible in selected oligometastatic NSCLC

497 浏览 · 10 赞 · 3 转发 · 0 回复

会议摘要

2700RO按 Rapid oral 1: NSCLC, metastatic 对上

Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort

https://esmocongress.esmo.org

806PNCT04787341 NCT04787341 NCT04787341按 Colon cancer 对上

Extended circulating tumor DNA (ctDNA) sequencing to optimize the selection between anti-EGFR rechallenge and other later lines in patients with RAS/BRAF wild-type metastatic colorectal cancer

https://esmocongress.esmo.org

NCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上

- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

https://esmocongress.esmo.org

来源：Narjust Florez, MD, FASCO · x.com